# Vir Biotechnology, Inc. (VIR) FY2026 Q2 Balance Sheet

- Company: Vir Biotechnology, Inc. (VIR)
- Period: As of 2026-06-30
- Filing: Q2 FY2026 10-Q, filed 2026-08-05, accession number 0001628280-26-053549
- Page: https://plicit.ai/financials/vir/fy2026-q2-balance-sheet
- Chart image: https://plicit.ai/charts/vir-fy2026-q2-balance-sheet-sankey.png

## Chart details

Balance sheet as of 2026-06-30. The chart shows assets, liabilities and equity at that date.

- **Assets**: 1,214,806,000 US dollars
- **Current assets**: 573,739,000 US dollars
- **Non-current assets**: 641,067,000 US dollars
- **Liabilities**: 232,313,000 US dollars
- **Current liabilities**: 94,961,000 US dollars
- **Non-current liabilities**: 137,352,000 US dollars
- **Equity**: 982,493,000 US dollars
- **Cash and cash equivalents**: 278,729,000 US dollars
- **Short-term investments**: 249,864,000 US dollars
- **Prepaid expenses and other current assets**: 39,084,000 US dollars
- **Equity investments**: 4,133,000 US dollars
- **Restricted cash and cash equivalents, current**: 1,929,000 US dollars
- **Long-term investments**: 475,016,000 US dollars
- **Operating right-of-use assets**: 59,391,000 US dollars
- **Property and equipment, net**: 50,430,000 US dollars
- **Other assets**: 24,647,000 US dollars
- **Goodwill**: 16,937,000 US dollars
- **Intangible assets, net**: 7,702,000 US dollars
- **Restricted cash and cash equivalents, noncurrent**: 6,944,000 US dollars
- **Accrued and other liabilities**: 77,207,000 US dollars
- **Accounts payable**: 17,754,000 US dollars
- **Operating lease liabilities, noncurrent**: 84,137,000 US dollars
- **Contingent consideration obligation, noncurrent**: 34,340,000 US dollars
- **Other long-term liabilities**: 18,875,000 US dollars
- **Additional paid-in capital**: 2,230,464,000 US dollars
- **Common stock, $0.0001 par value; 300,000,000 shares authorized as of June 30, 2026 and December 31, 2025; 169,185,671 and 139,474,954 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively**: 17,000 US dollars
- **Preferred stock, $0.0001 par value; 10,000,000 shares authorized as of June 30, 2026 and December 31, 2025; no shares issued and outstanding as of June 30, 2026 and December 31, 2025**: 0 US dollars
- **Accumulated deficit**: negative 1,243,386,000 US dollars
- **Accumulated other comprehensive loss**: negative 4,602,000 US dollars
- **Gross equity (calculated)**: 2,230,481,000 US dollars. Net equity plus the magnitudes of its negative contributions equals gross positive equity. The negative contributions enter this reconciliation as add-backs; their filed signs stay negative.

### Chart connections

- Assets equal liabilities plus consolidated equity. Consolidated equity includes noncontrolling interests when reported.
- Treasury shares and other negative equity contributions reduce equity.